GlassScriptPhysician profile
Pamela Pirzada
NPI 1932288693
$10,116.61
in general payments reported to CMS, 2019-2025
35 companies · $2,050 in 2025
The $2,050 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,038 · 2020: $1,538 · 2021: $1,209 · 2022: $877 · 2023: $1,035 · 2024: $1,371 · 2025: $2,050.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,456.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,455.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,780.08 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $831.16 | 2019-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $789.97 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $626.22 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $511.95 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $495.86 | 2025 | Caplyta |
| Novo Nordisk INC | $479.48 | 2019-2025 | Wegovy |
| Allergan, INC. | $369.51 | 2019-2021 | |
| Axsome Therapeutics, INC. | $276.87 | 2024-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.61 | 2019 | |
| Alkermes, INC. | $271.07 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Sanofi-Aventis U.S. LLC | $256.25 | 2019-2021 | |
| Boston Scientific Corporation | $255.53 | 2019-2023 | Watchman Access System |
| Indivior INC. | $246.66 | 2023-2025 | Sublocade |
| Astellas Pharma US INC | $141.15 | 2024 | Veozah |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $137.89 | 2020-2023 | Immunocap |
| Amarin Pharma, INC. | $130.89 | 2019 | |
| Braeburn INC. | $130.64 | 2024-2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $127.53 | 2025 | Fanapt |
| Ucb, INC. | $126.04 | 2019 | |
| Esperion Therapeutics, INC. | $124.55 | 2020 | |
| Impel Pharmaceuticals INC. | $112.26 | 2022 | |
| Cequr Corporation | $110.50 | 2024 | Cequr Simplicity |
| Biohaven Pharmaceuticals, INC. | $85.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $67.14 | 2019-2020 | |
| Paratek Pharmaceuticals, INC. | $61.75 | 2024-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $55.97 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $43.05 | 2022 | |
| Orexo US, INC. | $42.53 | 2022-2023 | |
| Exact Sciences Corporation | $41.96 | 2024-2025 | Cologuard Collection Kit |
| Radius Health, INC. | $39.82 | 2024-2025 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $33.36 | 2021 | |
| Shire North American Group INC | $15.63 | 2019 | |
| Zyla Life Sciences, INC. | $12.34 | 2019 | |
| Glaxosmithkline, LLC. | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pamela Pirzada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.